In a stride forward for women’s health and cervical cancer prevention, Asieris Pharmaceuticals has declared the successful completion of its Phase III clinical trial for APL-1702 (Cevira), a non-surgical treatment aimed at cervical high-grade squamous intraepithelial lesions (HSIL). This significant milestone could shift the paradigm in treating this precancerous condition, offering a less invasive alternative to surgery, and may particularly benefit women…
NK:IO, a startup working on natural killer (NK) cell biology applied to the development of exceptionally potent, off-the-shelf cell therapies targeting solid tumours, has raised an additional £1.2M in funding to advance its work. This brings total equity financing to £3.2M and will enable the company to reach key milestones in progressing its differentiated NK cell therapy candidates into development. The £3.2M…
You’ve found some of our exclusive Inner Circle Content. This article is only available for our Inner Circle Members. To read on: Sign in to your Inner Circle account to access this content. If you aren’t a member yet and would like to find out more about our Inner Circle program or sign up, click here.
You’ve found some of our exclusive Inner Circle Content. This article is only available for our Inner Circle Members. To read on: Sign in to your Inner Circle account to access this content. If you aren’t a member yet and would like to find out more about our Inner Circle program or sign up, click here.
Israel-based Nevia Bio has raised $3.1M in seed funding to accelerate its mission to revolutionize the early detection of diseases affecting women. The startup, which has rebranded from its former name Gina Life, specializes in developing machine learning algorithms capable of identifying early indicators of women’s health issues, such as ovarian cancer. The latest funding round saw participation from MindUP Digital Health…
Delphinus Medical Technologies, a pioneer in dense breast medical imaging, has secured $12M in growth capital from Trinity Capital. The funding will accelerate the adoption of their SoftVue 3D Whole Breast Tomography System, which enhances early breast cancer detection. The SoftVue system gained FDA approval in 2021 as an adjunct to digital mammography for screening asymptomatic women with dense breast tissue. Addressing…
In a stride towards the development of innovative treatments for cancer, the U.S. Food and Drug Administration (FDA) has granted approval for the Phase I/II clinical trials of LBL-033, an anti-MUC16/CD3 bispecific antibody developed by Leads Biolabs. The biotech company is set to investigate the safety, efficacy, and pharmacokinetics of LBL-033 in combating advanced solid tumors, including ovarian cancer. This bispecific antibody,…
Mithra Pharmaceuticals and BCI Pharma, have announced promising preliminary data from their CSF-1R inhibitor program. The research indicates that Mithra’s lead CSF-1R inhibitor compound displays significant anti-tumor activity, and may work synergistically with PD-1 cancer immune checkpoint inhibitors. The CSF-1R inhibitor demonstrated its efficacy in three preclinical cancer models, modulating the tumor microenvironment and potentially reducing tumor growth by up to 59%.…
